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Abstract 21 
During sexual transmission, the large genetic diversity of HIV-1 within an individual is 22 
frequently reduced to one founder variant that initiates infection. Understanding the drivers of 23 
this bottleneck is crucial to develop effective infection control strategies. Little is known about 24 
the importance of the source partner during this bottleneck.  To test the hypothesis that the 25 
source partner affects the number of HIV founder variants, we developed a phylodynamic model 26 
calibrated using genetic and epidemiological data on all existing transmission pairs for whom the 27 
direction of transmission and the infection stage of the source partner are known. Our results 28 
suggest that acquiring infection from someone in the acute (early) stage of infection increases the 29 
risk of multiple founder variant transmission when compared with someone in the chronic (later) 30 
stage of infection. This study provides the first direct test of source partner characteristics to 31 
explain the low frequency of multiple founder strain infections. 32 
 33 
34 
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Main Text 35 
Sexual transmission of HIV-1 results in a viral diversity bottleneck due to physiological barriers 36 
as well as viral or cellular constraints that prevent most genetic variants within the source partner 37 
from establishing onward infection (1–3). Indeed, this diversity bottleneck results in around three 38 
quarters of new infections being founded by a single genetic variant (4–9). The extent of genetic 39 
diversity transmitted to a new partner is a crucial determinant in understanding the efficacy of 40 
putative vaccines and may shed light on the transmission of drug resistance to treatment naive 41 
individuals. 42 
  43 
The factors leading to the diversity bottleneck during sexual transmission can be broadly 44 
categorized as those determined by the source partner—such as viral load and viral diversity 45 
available for transmission (10), those determined by the recipient partner—such as target cell type 46 
and availability in the genital or rectal mucosa (e.g. (3, 11, 12)), and those connected with viral 47 
characteristics—such as glycosylation profiles and cell tropism (reviewed in (13)). While the 48 
impact of the recipient partner and the characteristics of transmitted founder variants have been 49 
widely discussed, little is known about how the source partner affects the viral diversity bottleneck. 50 
Modelling work suggests that infection stage of the source partner at the point of onward 51 
transmission may be a key driver in determining the number of transmitted variants (14). However, 52 
there is currently no empirical evidence to suggest how the infection stage of the source partner 53 
influences the viral diversity bottleneck. This gap has arisen because analyses are routinely 54 
conducted on individuals without information on the partner from whom they acquired infection. 55 
Phylogenetic analyses now offer a possible solution to this impasse. 56 
  57 
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Phylogenetic trees are representations of the ancestral relationships of organisms with the tips of 58 
the tree representing those that are sampled, the internal nodes representing their inferred 59 
common ancestors, and the branches as the evolutionary pathways between these actual and 60 
inferred individuals. When phylogenetic trees are constructed using sequence data from both 61 
partners in an HIV transmission pair, the relationship between the evolutionary histories of both 62 
sets of viral samples may reflect epidemiological relationships between the two individuals (15-63 
17). Previous modelling studies suggest that the evolutionary histories of the viral populations in 64 
both partners can provide important information, such as the direction of transmission (15) and 65 
the number of transmitted founder variants (18). For this, each putative transmission pair can be 66 
classified into one of three ‘topologies’ that defines the evolutionary relationship between the 67 
viral populations of the two partners: monophyletic-monophyletic (MM, where the sequences 68 
from each partner form separate groups), paraphyletic-monophyletic (PM, where the sequences 69 
from one partner are embedded in the sequences from the second partner), or a combination of 70 
paraphyletic and polyphyletic (PP, where sequences from both partners are interspersed) (Fig. 71 
1A). The number of monophyletic clusters in a PM (one) or PP (more than one) tree can be 72 
interpreted as the minimum number of transmitted founder variants. In practice, however, many 73 
factors may influence epidemiological interpretations from phylogenetic trees such as sampling 74 
times, sampling density of the viral populations and phylogenetic signal (19, 20).  75 
 76 
Here we present a data-driven phylodynamic approach to overcome these empirical and 77 
methodological issues to evaluate the impact of the source partner’s infection stage and route of 78 
exposure on the HIV diversity bottleneck (Fig. 1B, C). We first retrieved all available genetic 79 
and epidemiological information from published HIV sexual transmission pairs where the 80 
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direction of transmission is known, and kept for further analysis those pairs for whom 81 
transmission could be classified as having occurred in the source partner’s acute stage (≤90 days 82 
after his/her infection) or chronic stage (later than 90 days after his/her infection). After further 83 
stratifying pairs into heterosexual (HET) and men-who-have-sex-with-men (MSM) risk groups, 84 
we found a significant difference in the timing of transmission between the two risk groups. 85 
Specifically, 10 of 36 MSM pairs were the result of acute stage transmission compared with 1 of 86 
76 of HET pairs (Fig. 2).   87 
 88 
Fig. 1: Methods schematics. A) Phylogenetic tree topology class of known transmission pairs that have 89 
previously been used as a proxy for calculating the minimum number of founder variants transmitted to 90 
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the recipient: trees of class MM and PM both suggest a minimum of one founder variant while trees of 91 
class PP suggest a multiple founder variants, with the minimum number of founder variants being the 92 
number of recipient clades embedded in PP trees (here shown as two). B) Pipeline of phylodynamic 93 
analysis (LANLdb, Los Alamos National Laboratory HIV sequence database) where teal represents data 94 
or analysis output and white represents methods and analysis. An example of a standardised transmission 95 
timeline for a known source-recipient pair is provided in panel C. C) Schematic of the transmission pair 96 
model simulation that shows the transmission and sampling timelines. The simulated number of virus 97 
particles transmitted to the index case, and the source and recipient partners (!", !$, !% respectively) are 98 
shown on the transmission events timeline. 99 
 100 
We then performed Bayesian phylogenetic tree reconstruction on the genetic sequences of the 101 
transmission pairs and classified the topology class of each tree in the posterior distribution as 102 
monophyletic-monophyletic (MM), paraphyletic-monophyletic (PM) or paraphyletic-103 
polyphyletic (PP).  The most likely topology class was PM (65% and 61% for HET and MSM, 104 
respectively), but with a higher number of PP trees in the MSM group (P=0.056, Fig. 2). This 105 
result has previously been reported as indicative of a higher number of founder variants for 106 
MSM (18). However, when we stratify the topology class by whether the source partner was in 107 
acute or chronic infection at the time of transmission, our results indicate that the infection stage 108 
of the source is the primary driver for any observed differences in topology class. Specifically, 109 
there is no difference between the HET and MSM groups in the PM/PP topology class ratio 110 
when transmission occurs in the chronic stage of infection (P=0.570). Note that only one HET 111 
transmission occurs during the acute stage, and the topology class for this pair is PP. These 112 
results remain qualitatively consistent when only data were analysed from the 66% of 113 
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transmission pairs for whom the posterior trees gave a certainty of over 95% for the most 114 
frequent topology class (Fig. S3). These results indicate that infection stage of the source partner, 115 
and not risk group per se, influences the diversity bottleneck at transmission. 116 
 117 
 118 
Fig. 2: Phylogenetic findings from the empirical transmission pairs. Fraction of phylogenetic tree 119 
topology class (MM: Monophyletic-Monophyletic, PM: Paraphyletic-Monophyletic and PP: Paraphyletic-120 
Polyphyletic) where each tree topology class is classified as the most frequent topology class of each 121 
posterior distribution per transmission pair. Results are stratified by risk group: 76 heterosexual (HET) 122 
pairs and 36 men-who-have-sex-with-men (MSM) pairs) and infection stage of the source partner at 123 
transmission (11 acute pairs defined as <90d post infection and 101 chronic pairs defined as ≥90d post 124 
infection).  125 
To test whether these empirical findings are indicative of a smaller diversity bottleneck in the 126 
chronic stage of HIV infection, we developed a phylodynamic framework in which we simulated 127 
the epidemiologic characteristics of each HET and MSM transmission pair, the timing of their 128 
sequence sampling, the transmission of virus particles, and the within-host genetic evolution in 129 
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both the source and recipient (Fig. 1B). Specifically, using the epidemiological information from 130 
the transmission pairs, we simulated phylogenies under a coalescent model before generating 131 
genetic sequences from these simulations and performing Maximum Likelihood (ML) 132 
phylogenetic reconstruction on these simulated sequences. We classified each of these simulated 133 
trees as MM, PM or PP and determined the frequency of each topology class (i.e. the fraction of 134 
simulated trees that are classified as MM, PM and PP) for each simulated transmission pair 135 
across all the simulated sequences.  However, as we could not directly observe the number of 136 
virus particles that are transmitted between source and recipient, we repeated the simulation of 137 
phylogenetic trees for each transmission pair under a range of plausible values of virus particles 138 
transmitted. By fitting the simulation output topology class distribution to the topology class 139 
distribution from the empirical phylogenetic trees using maximum likelihood inference, we then 140 
determined the most likely number of transmitted virus particles for each transmission pair and 141 
used this best fit model for further analysis.  Note that two or more virus particles may have the 142 
same genetic sequence and would constitute a single founder variant (or haplotype), discussed 143 
later. Further, due to the analysis conditioning on extant lineages, we use the term ‘founder 144 
variants’ to describe those transmitted variants that found detectable viral lineages, thereby 145 
ignoring variants that are transmitted but the lineages of which become extinct. 146 
Our fitting procedure selects a best fit model that clearly delineates between transmission pairs 147 
between whom one virus particle is transmitted (75% of pairs) and those between whom more 148 
than one virus particle is transmitted (25% of pairs, Fig. 3A). While there is a high degree of 149 
confidence in the result when one particle is transmitted, there is often uncertainty around the 150 
exact number when multiple particles are transmitted (Fig. 3A). Importantly, we found acute 151 
stage transmissions are more likely to lead to multiple particle infections compared with chronic 152 
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stage transmissions (73% vs. 20%, P = 0.0005). The topology class of the simulated 153 
phylogenetic trees is strongly influenced by the number of virus particles being transmitted (Fig. 154 
3B). PM trees are more commonly found in the pairs that are better described by a model with a 155 
single transmitted virus particle (81%) whereas PP trees appeared more often when multiple 156 
particles are likely to have been transmitted (86%).  157 
 158 
 159 
Fig. 3: The estimated number of transmitted virus particles for the 112 transmission pairs. The 160 
estimates of transmitted virus particles for each transmission pair were calculated by choosing the model 161 
simulation that generated a phylogenetic tree topology class distribution (that is, the number of MM, PM 162 
and PP trees constructed from the simulated genetic sequences) that best matched the topology class 163 
distribution from the phylogenetic trees constructed from the empirical genetic sequences.  A) Maximum 164 
likelihood number of virus particles founding recipient infections, !%∗ , for each pair (stacked points) with 165 
95% confidence intervals (lines) grouped by stage of infection (acute, 11 pairs or chronic, 101 pairs) and 166 
risk group (76 heterosexual pairs, HET and 36 men-who-have-sex-with-men pairs, MSM). B) Maximum 167 
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likelihood number of virus particles founding recipient infections coloured by topology class of the 168 
phylogenetic tree constructed from the simulated genetic sequences.  169 
 170 
For each transmission pair, we then simulated the genetic sequences of the transmitted viral 171 
population under the best fit virus particle model and calculated the most likely number of 172 
founder variants for each transmission pair (i.e. the number of distinct haplotypes). The median 173 
number of founder variants transmitted across all pairs is 1 (range: 1-11, Fig. 4A). Using the full 174 
distribution of the number of transmitted founder variants for each pair, we also calculated the 175 
probability that a single founder variant was transmitted to the respective recipient. Our results 176 
suggest that across all pairs in both risk groups, the mean probability of observing one founder 177 
variant is 0.73. Stratifying by risk group, we find there is a higher probability that one founder 178 
variant founds HET infections than MSM infections (a geometric mean of 0.80 vs. 0.63, Fig. 179 
4B). However, these risk group differences mostly disappear when we stratify the results by the 180 
infection stage of the source. Here, for example, when only chronic stage transmissions are 181 
considered, there is no difference in the probability of one founder variant between MSM 182 
transmissions and HET transmissions (means of 0.80 vs 0.71, P=0.398), and the pairwise 183 
diversity at transmission is similar between both groups (Fig. 4C). In contrast, when stratifying 184 
solely by infection stage of the source partner, we find that transmission during the acute stage 185 
has a much lower probability of one founder variant than during the chronic stage (means of 0.40 186 
vs. 0.77) with a higher median number of founder variants transmitted, when only the most likely 187 
number of founder variants for each pair is considered (2 vs. 1, Fig. 4A). Nonetheless, if multiple 188 
founder variant transmission does occur, our results suggest that the number of founder variants 189 
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is higher during chronic stage transmission, consistent with a higher diversity measure during 190 
this later stage of infection (Fig. 4C).  191 
From these results, therefore, there is approximately double the chance of multiple founder 192 
variant transmission during acute stage infection across both risk groups (relative risk = 0.52).  193 
Assuming that transmission risk is weighted towards early transmission such that half of all 194 
index case to source partner transmissions occur after 90 days of index case infection leads to 195 
qualitatively similar results (Supplementary Materials).  Similarly, calibrating the simulation 196 
model to bootstrapped samples rather than Bayesian posterior distributions leads to similar 197 
results (Supplementary Materials). 198 
 199 
Our results suggest that there is an association between tree topology class and multiple founder 200 
variant transmission, with 95% of MM and PM trees being due to one founder variant (Fig. 4D). 201 
However, the number of embedded recipient clades is not always a proxy for the minimum 202 
number of founder variants transmitted. For example, in chronic stage transmission, 11% of PP 203 
topology class trees were due to single founder variant transmission (Fig. 4D). It is important to 204 
stress that a PP topology class outcome may occur not only due to multiple genetically distinct 205 
virus populations founding recipient infections but may also reflect a lack of phylogenetic signal 206 
in the data; for instance, the sampled sequence lengths that gave rise to PP trees was on average 207 
shorter than those for MM (P=0.096) and PM (P=0.004). Across both infection stages, we find 208 
that if MM, PM or PP is assigned as the most likely tree topology class, then 92%, 96% and 15% 209 
of transmissions are due to a single founder variant, respectively.  210 
 211 
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We have used a combination of empirical data and phylodynamic model simulation to evaluate 212 
the role of infection stage at transmission and route of transmission on the number of virus 213 
particles transmitted during sexual HIV exposure. This makes three important advances on 214 
previous work. First, it is the first empirically-based study that fits a model to data to understand 215 
the role of the source partner in multiple founder variant transmission. Second, while we use 216 
previously developed topology classification of phylogenetic trees to understand HIV 217 
transmission pairs, we extend this methodology by calibrating a phylodynamic model to 218 
empirical data. This new approach provides a means to validate the untested assumption that the 219 
number of embedded recipient partner lineages in a phylogenetic tree directly corresponds to the 220 
minimum number of founder variants transmitted. Third, our phylodynamic model explicitly 221 
incorporates virus particle number and the identity of genetic sequences. This advance produces 222 
results that contrast with previous work that has shown the number of founder variants has little 223 
impact on the topology class of the phylogenetic tree when only overall genetic diversity, rather 224 
than sequence identity, is tracked (15).  225 
 226 
The relative importance of acute and chronic stages of HIV in determining both the number of 227 
virus particles and the number of founder variants transmitted is consistent with a recent 228 
modelling study (14). However, our study finds higher proportions of infections initiated by 229 
multiple founder variants overall during these two stages. This difference is likely due to the 230 
assumptions related to how the stages of infection are defined as well as the relative importance 231 
of transmission during late infection. Specifically, the previous modelling study finds that two 232 
thirds of multiple founder variant transmission occurs during the pre-AIDS stage of infection 233 
which is assumed to have both a high viral load and large haplotype diversity. If later stages of 234 
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Fig. 4: Phylogenetic findings from the calibrated simulations. A) Frequency of number of transmitted 236 
founder variants for transmission pairs by either infection stage of source partner at transmission (left) or 237 
risk group (right). The number of multiple founder variants is calculated as the modal simulated value. B)  238 
Probability of one founder variant in the recipient for each pair stratified by infection stage of the source 239 
partner at transmission. C) Probability density distribution of maximum diversity (proportion of sites that 240 
differ) in the recipient partner across all simulations with more than one haplotype stratified by infection 241 
stage of the source at transmission. D) Number of founder variants coloured by topology class of the 242 
phylogenetic tree constructed from the best fit model of the simulated genetic sequences.  243 
 244 
infection account for disproportionately less transmission then the previous model would predict 245 
higher proportions of multiple founder variant transmission in both the acute and chronic stages 246 
of infection, becoming more consistent with empirical estimates from our analysis. By contrast, 247 
our study is agnostic about the relative importance of early and late transmission and does not 248 
differentiate between chronic and a pre-AIDS stage of infection, which cannot easily be 249 
identified through analysis of empirical data.  250 
 251 
Data from four of the MSM transmission pairs in this study have previously been used to 252 
estimate the number of variants founding infection using a combination approach of single 253 
genome amplification (SGA), direct amplicon sequencing and mathematical modelling (7). Our 254 
results broadly agree with this previous analysis, with both analyses suggesting two recipients 255 
were infected with one founder variant and one recipient was infected with multiple founder 256 
variants (our analysis suggests a mean of 2-3 founder variants and the previous analysis suggests 257 
3 founder variants); there was disagreement with results from a fourth recipient, for whom a 258 
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single founder variant was 13% probable in this study (with a mode of 2 founder variants) but 259 
the most likely outcome in the previous analysis.  Small differences likely arise because this 260 
study uses sequence data from both partners to evaluate the transmission of multiple founder 261 
variants to the recipient partner. These extra data can be used to parameterize a mathematical 262 
model that accounts for the evolutionary relationship between the virus samples from both 263 
partners, rather than relying solely on accumulating diversity. Specifically, neglecting the extent 264 
of genetic similarity between the source and recipient virus samples might misattribute 265 
borderline cases of diversity accumulation. 266 
Our study finds a median of one founder variant and a maximum of 11, with little difference 267 
between HET and MSM risk groups. When only multiple founder variant transmissions are 268 
considered, our study finds a median of 2-3 founder variants. These values are consistent with a 269 
previous pooled analysis using results from four analyses that used the current gold-standard 270 
SGA combination approach as above (9).  271 
At present, the genetic determinants of  HIV-1 disease progression are not clear. However, it is 272 
important to note that even small differences between genotypes can have important clinical 273 
outcomes. For instance, single polymorphisms can affect replication capacity (21), or can lead to 274 
primary non-nucleoside reverse transcriptase inhibitor resistance with different amino acids 275 
changes at the same position conferring equivalent levels of resistance (22). 276 
Previous studies have disagreed over the extent to which the elevated risk of transmission during 277 
the acute stage of infection (reviewed in (23)) is driven by increased viral load, elevated per 278 
particle transmission probability or other behavioural factors such as high rates of sex partner 279 
change or concurrent partnerships (24-29). Here, while we find strong evidence to support the 280 
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fact that acute stage transmissions are characterised by more virus particles and variants 281 
founding infection, this result alone cannot disentangle virus- and host-related drivers of elevated 282 
transmission. For example, the higher number of variants being transmitted during acute 283 
infection could arise if the number of transmissible variants declines as infection progresses or, 284 
because with more particles being transmitted, there are more opportunities for multiple variants 285 
to found infection (14,30) However, our study can shed light on the eight times elevated per-286 
exposure risk of infection that has been found for MSM relative to HET transmission (31-32). In 287 
particular, the lack of difference in both the number of virus particles and the number of founder 288 
variants that establish infection after transmission from a chronically infected source in HET and 289 
MSM suggests that the observed heightened acquisition risk for MSM could in part be due to 290 
sampled MSM individuals being more likely to be in the acute stage at the time of transmission 291 
(14, 27). Whether MSM partners are more likely to be sampled earlier in infection because of 292 
sampling procedures or because MSM are indeed more likely to transmit during early infection is 293 
unclear. While this observation raises the possibility that the role of sexual risk group in itself 294 
may have less of an impact on the transmission of multiple founder variant probability, from a 295 
pragmatic perspective, if more MSM infections are indeed caused by acute stage transmissions, 296 
the evolutionary and epidemiologic impact on public health will be the same irrespective of the 297 
mechanism. 298 
 299 
There are two primary limitations to acknowledge. First, our model assumes a single 300 
transmission event between each source and recipient partner. Without detailed knowledge of the 301 
transmission pairs, we cannot distinguish between multiple infections each with a single founder 302 
variant and a single infection with multiple founder variants; if for some pairs, the former were 303 
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true then this might suggest an elevated transmission rate during the acute stage, as has been 304 
observed previously (28, 29). Second, our phylodynamic framework does not account for the 305 
effect of selection and recombination. Specifically, selection, such as that for viruses which use 306 
the CCR5 co-receptor (33), is thought to occur at the point of transmission , although the strength 307 
may be dependent on the route of transmission (34).  308 
 309 
Our study finds that the transmission of multiple HIV-1 founder variants is determined by 310 
infection stage of the source partner, with transmission of more founder variants of HIV-1 in 311 
acute compared with chronic infections. These findings stress that epidemiological or clinical 312 
analysis of known transmission pairs should account for potential mediation by stage of 313 
transmission when evaluating the effect of sexual risk group.  314 
 315 
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Materials and Methods 20 
 21 
Data collation on linked transmission pairs 22 
We automatically retrieved all HIV sequence data for men-who-have-sex-with-men (MSM) and 23 
heterosexual (HET) HIV transmission pairs for whom the direction of transmission is reported 24 
from The Los Alamos National Laboratory (LANL) HIV sequence database up to February 25 
 2 
2019, such that each transmission pair comprise a ‘source’ and a ‘recipient’ partner. For each 26 
partner in the transmission pair we collected the following clinical and epidemiological data: (i) 27 
date of infection or time of infection prior to sampling, (ii) date of seroconversion or date of 28 
seroconversion prior to sampling, (iii) Fiebig stage at the time of sampling, (iv) date of sampling 29 
or time of sampling prior to infection, (v) number of sequences, (vi) genomic region, (vii) HIV 30 
subtype, and (viii) reported risk group. For each set of these transmission pair data we estimated, 31 
relative to the transmission time to the recipient partner (time = 0): (i) the time of transmission to 32 
the source partner, (ii) the time of the sampling of the source partner, and (iii) the time of 33 
sampling for the recipient partner (Fig. 1, Supplementary Text). We excluded all transmission 34 
pairs from further analysis for whom these three times could not be determined or for whom 35 
either partner has fewer than five sequences for all sampling times. For our base case analysis, 36 
we used the longest available genomic region with five or more sequences per partner. If more 37 
than one sampling time is available for any of the individuals, we selected the sample closest in 38 
time to the recipient infection.  39 
Epidemiological data and sequence retrieval 40 
For the ease of replicating our results and using existing transmission pair data for other 41 
purposes, we developed a Python script to automatically retrieve epidemiological and metadata 42 
for each transmission pair from the Los Alamos National Laboratory HIV sequence database 43 
(LANLdb). This script downloads the following data from both the source and recipient partners 44 
to a .csv file using as input the cluster and patients ids from LANLdb: (i) time of infection, (ii) 45 
time of seroconversion, (iii) Fiebig stage at the time of sampling, (iv) number of sequences, (v) 46 
genomic region, (vi) HIV subtype, (vii) reported risk group and (viii) GenBank accession IDs.  47 
 48 
 3 
Next we used the downloaded GenBank accession IDs to automatically retrieve (ix) viral genetic 49 
sequences and (x) sampling dates (calendar dates) from GenBank using an R script. If 50 
information from (i) to (x) were missing for any individual, we manually retrieved these values 51 
from the original manuscripts where possible.  52 
 53 
Completed datatables from these automatic and manual processes are provided at 54 
github.com/AtkinsGroup. 55 
 56 
Transmission timelines 57 
For each transmission pair, we define time = 0 as the time of recipient infection. We then 58 
calculated, using the data table retrieved, i) the time of infection of the source, ii) the time of 59 
sampling of the source, iii) the time of sampling of the recipient.  60 
 61 
To estimate these times, we first calculated days from infection for both the source and the 62 
recipient partners. When these values are not given explicitly, we calculated them from time 63 
since seroconversion estimates or from Fiebig staging results. Specifically, we interpret 64 
seroconversion as the individual reaching Fiebig stage III (ELISA positive) that occurs between 65 
22-37 days after infection and Fiebig stages I (viral RNA positive) and II (18-34) occurring 13 66 
days and 28 days after infection, respectively (35).  For all the pairs where a range of possible 67 
values is calculated, and for when a calendar month is provided, we incorporated the uncertainty 68 
around the infection and sampling times by assuming all values in these ranges are equally 69 
plausible and uniformly sampled within these range to account for the uncertainty.  70 
 4 
 71 
For some pairs, the source was classified as ‘recent’ or ‘late’ at the time of transmission to the 72 
recipient partner. In these cases, we do not have an exact point to call time = 0. Therefore, for 73 
these pairs, for each simulation, we sample with replacement the time between source and 74 
recipient infections from the other pairs for whom we have previously classified as acute (<90 75 
days delay), and chronic (90 days or more delay), sampling from the same risk group (MSM or 76 
HET) in each case. 77 
All calculations, corresponding notes and final transmission times for each pair are provided at 78 
github.com/AtkinsGroup and visualised in Fig. S1. 79 
 5 
 80 
Fig. S1: Infection and sampling times of the source and recipient for all the 112 transmission pairs 81 
analysed. Individual points denote exact times and lines denote uniform uncertainty in times. Source 82 
 6 
partners points/lines overlapping the green shaded area correspond to transmission pairs for whom 83 
transmission occurs during the acute stage.   84 
 85 
Empirical transmission pair analysis  86 
Tree reconstruction: For each of the included transmission pairs, we generated posterior sets of 87 
phylogenetic trees. For this, we first constructed alignments using Muscle v3.8.31 (36, 37) with 88 
subtype specific reference sequences retrieved from the LANL HIV sequence database. Using 89 
these alignments, we built phylogenetic trees with MrBayes 3.2.7 (38, 39) under the assumption 90 
of a general time-reversible (GTR) nucleotide substitution model with the addition of invariant 91 
sites (I) and a gamma distribution of site rates. We constrained sequence data to be monophyletic 92 
with respect to the reference sequences to root the tree but ingroup relationships were 93 
unconstrained to avoid any topology class bias. We ran two Markov chains each with 30 million 94 
iterations, from which we sampled every 3,000th after discarding the first 50% as burn-in which 95 
provided an average standard deviation of split tree frequencies of below 0.01 or an effective 96 
sample size of greater than 300. This gave an empirical posterior distribution of N = 5,000 97 
sample trees. In a sensitivity analysis, we tested the alternative method of using maximum 98 
likelihood phylogenetic tree reconstruction with bootstrapping. 99 
 100 
Empirical topology class: We classified each of the resulting phylogenetic trees in the posterior 101 
distribution as either monophyletic-monophyletic (MM), or paraphyletic-monophyletic (PM), or 102 
paraphyletic-polyphyletic (PP), to reflect the cladistic relationship between the lineages from 103 
both individuals (Supplementary Text). Each transmission pair,!, is then described as a triplet of 104 
probabilities, "#, denoting the frequency of each topology class within the !th pair’s posterior 105 
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distribution "# = 	 {'#())},	∈. 	= 	 {Pr	()	|	!)},∈.	 where ∑ Pr()|!) = 1,∈. 	and 4	 ∈106 	{MM, PM, PP}. 107 
 108 
Simulated transmission pair analysis 109 
We simulated the transmission of virus particles and within-host evolution, accounting for the 110 
epidemiological characteristics for each transmission pair. For each transmission pair, we 111 
simulated a chain of three HIV infections: (i) an unsampled index case who infected the source 112 
after three years of their own infection during their chronic stage to reflect that the majority of 113 
both HET and MSM transmission pairs transmitted during the chronic stage (101/112 pairs). In a 114 
sensitivity analysis we accounted for the assumption that transmission rate may be higher during 115 
the acute stage, with half of the index to source transmissions occurring after 90 days and the 116 
remaining half after three years, (ii) the source individual of the transmission pair, and (iii) 117 
finally the recipient individual of the transmission pair.  For each individual within each trio, we 118 
simulated viral phylogenies that reflect between- and within-host viral evolution using 119 
VirusTreeSimulator (40), using as input the respective epidemiological and clinical information 120 
(Supplementary Text). We used a within-host effective population size consistent with that 121 
parameterized by the PANGEA-HIV study with the following logistic model parameters: initial 122 
effective population size (78) is 1, viral generation time (9) is 1.8 days, effective population per 123 
year growth rate (:) is 2.85022, and time to half the carrying capacity of the viral population 124 
();8) is 2 years (40).  For each transmission pair, we simulated a dated viral phylogeny that has 125 
the same number of tips as the number of retrieved sequences per partner and that is sampled at 126 
the respective sampling times for the source and recipient partner (Supplementary Text). For 127 
each recipient partner infection, we assume that a total of <= virus particles founded the 128 
 8 
infection. For each simulation, we further assume a total of <>  virus particles founding infection 129 
of the source. We assume <= takes values between one and a maximum of 12 and varied <>  130 
between one and two (Supplementary Text). We assume that the virus samples from each 131 
recipient is representative of the within-host diversity, and that each founding virus particle has 132 
an extant lineage. Therefore, we first assigned each sample (tip) of a phylogeny as a descendant 133 
of one of the <=virus particles. If there were more than 12 samples then the remaining tips were 134 
assigned randomly to the <= = 12 virus particles. If there were fewer than 12 samples, then we 135 
constrained the number of founding virus particles, <=, to equal the number of samples. For 136 
every transmission pair, and for each value of <= and <>, we simulated 100 viral phylogenies. 137 
 138 
For every simulated viral phylogeny, we simulated transmitted sequences by adding dummy 139 
nodes with a negligibly short branch length after the transmission time. We then simulated the 140 
evolution of nucleotide sequences along the tree using Seq-Gen (41) and a GTR + I + gamma 141 
substitution model. The length of the simulated sequences and the evolutionary tree scaling rate 142 
match each transmission pair’s empirical sequence data. For this, we used previously estimated 143 
empirically-derived within-host evolutionary rates (42) and the HXB2 sequence homologous to 144 
the pair’s sequence fragment as the ancestral sequence at the root. Every transmission pair 145 
simulation produces a tip sequence alignment and a number of founder sequences equal to the 146 
number of transmitted particles.  147 
 148 
Simulated topology class: We reconstructed a phylogeny using maximum likelihood inference in 149 
IQ-TREE 1.6.11 (43) and selected the best-fit nucleotide substitution model with ModelFinder 150 
(44). Each phylogeny was classified as either MM, PM or PP (Supplementary Text). 151 
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Consequently, for each transmission pair ! and each transmissibility model (i.e. number of viral 152 
particles founding infection of the recipient <=), we generated a triplet of probabilities @#,AB =153 CD#,ABE,∈. = Pr()|!, <=)}	,∈.  where ∑ Pr,∈. ()|!, <F) = 1	and 4	 ∈ 	 {MM, PM, PP}. 154 
 155 
Transmissibility model calibration 156 
For each transmission pair, we chose the most likely value of <= (the number of virus particles 157 
founding each recipient infection) by matching the posterior topology class from the empirical 158 
phylogenetic transmission trees with the simulated distribution of topology class. Specifically, 159 
for each transmission pair, !, we estimated the most likely number of viral particles founding 160 
each recipient infection <=∗ 	as the <= that maximises the multinomial likelihood function H#,AB =161 PrI"#	J@#,ABK = 	 L!∏ (LOP(,))!Q∈R ∏ D#,AB())LOP(,),∈. . For each transmission pair !, we calculated 162 
lower and upper confidence limits for <=∗  as the minimum and maximum values of <= that satisfy 163 H#,AB 	> 	 H#,AB∗ − 1.92  and H#,AB < 	H#,XB∗ + 1.92, respectively (44, 45). For each transmission 164 
pair !, we retain the best fit model for further analysis such that there are <=∗  viral particles 165 
founding infection of the recipient.  166 
Haplotype analysis 167 
Probability of a single founder haplotype: For each transmission pair, !, from the best fit 168 
transmissibility model, we defined the random variables Z># and Z=# as the number of haplotypes 169 
that found infection of the source and the recipient partners, respectively.  We then calculated the 170 
probability of there being a single founder haplotype in the recipient, stratified by topology class 171 
of the simulated phylogenetic tree (MM, PM, PP) and the number of founder haplotypes, i, in the 172 
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source partner, [\#()), that is,  [\#()) = Pr	(ZF# = 1|Z]# = ^, )). Next, we defined the probability 173 
of a single founder haplotype in the recipient as a function of a tree topology, t, [#()) =174 PrIZF# = 1J)K = 	[_# Pr(Z] = 1) + [#`Pr	(Z> > 1). By assuming that the source partners are 175 
randomly selected from the general MSM or HET population in which the probability of a single 176 
founder variant has been calculated to be approximately 0.7 (14), we set, a:(Z> = 1) =177 0.7	and	a:(Z> > 1) = 	0.3. Finally, for each transmission pair, we calculated the probability of 178 
one founder haplotype given the observed triplet of empirical posterior topology classes "#, as 179 e# = 	∑ [#())'#())/7,∈. .    180 
 181 
Number of founder haplotypes by source partner infection stage: We stratified all the 182 
transmission pairs into two sets by the infection stage of the source partner. We classified the 183 
acute transmission set as those pairs for whom recipient infection is within 90 days of source 184 
infection (a set of nacute pairs), and the chronic transmission set as those pairs for whom recipient 185 
infection is 90 days or later after source infection (a set of  nchronic pairs). For each group, we 186 
calculated the mean probability of one founder haplotype being transmitted to the recipient in 187 
each set set as:  188 
eghijk# = 	 lm e##∈ghijknopqrs  189 
ehtuvXwh# = 	 lm e##∈htuvXwhnpxyz{|p  190 
Finally, we calculated the relative risk of one founder haplotype transmitted during the acute 191 
stage versus the chronic stage by e}~,Ä# /	e~ÅÇÉA\~# .  192 
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Statistical analysis 193 
We compare our results by using statistical tests and report the respective P-values. To compare 194 
proportions from count data we use the Fisher exact test (for two groups) and the chi-square test 195 
(for three groups), and we use the t-test when comparing differences between continuous 196 
variable values from two groups. 197 
 198 
Supplementary Text 199 
 200 
Transmission pairs sequence data 201 
Our alignments are provided at github.com/AtkinsGroup.  202 
On average, 22 (IQR 13-33) HIV sequences are obtained from the source and 21 (IQR 10-20) 203 
sequences from the recipient for the MSM pairs, and 21 (IQR 12-25) and 18 (IQR 9-22) for the 204 
HET source and recipient, respectively. All MSM sequence data belong to subtype B, while most 205 
heterosexual sequence data belong to subtype C (49%), followed by subtype B (22%), subtype D 206 
(21%), subtype A/A-like (7%) and unclassified subtype (1%). A total of 7 (19%) of the MSM 207 
pairs have near full genomes sequenced and the remaining pairs had env available (mean 1653 208 
nt, range 182-3827 nt). Ten (13%) of the HET pairs had near full genomes available, while 56 209 
(75%) pairs had env (mean 1321 nt, range 323-2582 nt), nine (12%) pairs had either pol or gag 210 
(mean 1484 nt, range 1375-1499 nt) and one pair had vif-LTR3 (4666 nt) sequenced. 211 
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 212 
Effect of number of founding virus particles in the source 213 
To assess whether the number of founding virus particles in the source partner affects the 214 
diversity of sequences founding infection in the recipient, we model a scenario where the index 215 
case transmitted one, two or six virus particles to the source partner at either one or three year(s) 216 
after infection. The source in turn transmits 1 to 6 virus particles to the recipient at 30 days 217 
(acute) or 1095 days (chronic) later. The simulation produces a dated viral phylogeny with tips 218 
sampled at either 30 (early) or 1065 days (late).  We model 1kb nucleotide sequences along the 219 
simulated viral phylogenies using the same method as in the main text. 220 
 221 
The genetic variation rapidly and steadily increases over time – the maximum diversity among 222 
transmitted haplotypes to the recipient was higher when the index case was infected for longer 223 
and the transmission to the recipient occurs during the chronic stage of the source (Fig. S2). 224 
When the source has more than one founding particle, this leads to a bimodal distribution of 225 
maximum diversity among transmitted founder variants within the recipient. The first and second 226 
mode represent maximum diversity when drawing the recipient founder haplotypes from either 227 
one or more than one viral population within the source, respectively. However, increasing the 228 
number of founding virus particles to more than two within the source only increases the density 229 
around the second mode without affecting the range of the maximum diversity distribution. This 230 
consistency occurs because increasing the number of founding virus particles in both 231 
transmission partners, increased the probability of drawing founding variants from different 232 
genetic pools in the source. However, the average maximum diversity of the founder variants 233 
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does not change because the source genetic pools evolved at the same rate and under the same 234 
evolutionary constraints with no selective advantage. This leads to genetic pools with equivalent 235 
cumulative genetic change but distinct identity. Taking this into account, we chose to model one 236 
or two founding virus particles within the source partner as we were interested in capturing some 237 
degree of variation in the transmitted haplotypes rather than multiple genetic identities per se. 238 
 239 
Fig. S2: Effect of number of founding virus particles in the source. 240 
 241 
 242 
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 243 
 244 
 245 
Effect of using a confidence threshold for assigning the topology class 246 
 247 
Fig. S3:  Phylogenetic findings of the empirical transmission pairs for whom the posterior trees 248 
gave a certainty of over 95% for the most frequent topology. Fraction of phylogenetic tree topology 249 
class (MM - Monophyletic-Monophyletic, PM - Paraphyletic-Monophyletic and PP - Paraphyletic-250 
Polyphyletic) where each tree topology class is classified as the most frequent topology class of each 251 
posterior distribution per transmission pair. Results are stratified by risk group: 76 heterosexual (HET) 252 
pairs and 36 men-who-have-sex-with-men (MSM) pairs) and infection stage of the source partner at 253 
transmission (11 acute pairs defined as <90d post infection and 101 chronic pairs defined as ≥90d post 254 
infection).  255 
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Effect of index partner stage of infection at transmission 257 
In the main analysis we assumed that all index cases transmit to the source partner after three 258 
years of infection. Here we also evaluated the results assuming the transmission risk was skewed 259 
towards early infection, with half of all simulations across all transmission pairs assuming index 260 
case transmission occurs during the acute stage (≤90d) and half occurs during the chronic stage 261 
(91d-3y). We find qualitatively similar results as our main analysis.  The median number of 262 
founder variants transmitted across all pairs is 1 (range: 1-5, Fig. S4A). Across all pairs in both 263 
risk groups, the mean probability of observing one founder variant is 0.73. Stratifying by risk 264 
group, we find there is a higher probability that one variant founds HET infections than MSM 265 
infections (a geometric mean of 0.79 vs. 0.61, Fig. S4B). In contrast, when stratifying solely by 266 
infection stage of the source partner, we find that transmission during the acute stage has a much 267 
lower probability of one founder variant than during the chronic stage (means of 0.38 vs. 0.78) 268 
with a higher median number of founder variants transmitted, when only the most likely number 269 
of transmitted founder variants for each pair is considered (2 vs. 1, Fig. S4A). From these results, 270 
therefore, there is still approximately twice the chance of multiple founder variant transmission 271 
during acute stage infection across both risk groups (relative risk is 0.48). 272 
 273 
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 274 
Fig. S4: Phylogenetic findings from the calibrated simulations with skewed transmission rate 275 
towards acute stage for the index case. A) Frequency of the number of founder variants for 276 
transmission pairs by infection stage of source partner at transmission and risk group. The number of 277 
transmitted founding variants is calculated as the modal simulated value. B)  Probability of one founder 278 
variant in the recipient for each pair stratified by infection stage of the source partner at transmission.  279 
 280 
Effect of constructing empirical data phylogenetic trees using maximum likelihood 281 
inference with bootstrapping 282 
In the main analysis we used Bayesian phylogenetic reconstruction to analyse the empirical 283 
sampled genetic data of each empirical transmission pair, using the respective posterior 284 
distribution to calculate the frequency of each topology class (MM, PM and PP). Here we 285 
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provide a sensitivity analysis to calculate the tree topology class distribution of the empirical 286 
sampled genetic data by maximum likelihood phylogenetic tree construction and bootstrapping. 287 
After bootstrapping the empirical data 100 times to calculate the frequency of MM, PM and PP 288 
topology classes for each transmission pair, we then proceeded using the same methodology as 289 
in the main text. That is, we fit the simulation model (parameterised with the pair-specific data) 290 
to the bootstrapped data individually for each transmission pair by comparing the frequencies of   291 
tree topology classes. Overall our results remained consistent with our main results, albeit with 292 
slightly lower probabilities of observing one founder variant. The median number of founder 293 
variants transmitted across all pairs is 1 (range: 1-11, Fig. S5A). Across all pairs in both risk 294 
groups, the mean probability of observing one founder variant is 0.62. Stratifying by risk group, 295 
we find there is a higher probability that one variant founds HET infections than MSM infections 296 
(a geometric mean of 0.67 vs. 0.53, Fig. S5B). Stratifying by infection stage of the source 297 
partner, we find there is a much lower probability of one founder variant during the acute stage 298 
than during the chronic stage (means of 0.31 vs. 0.66) with approximately twice the chance of 299 
multiple founder variant transmission during acute stage infection across both risk groups 300 
(relative risk is 0.47).  301 
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Fig. S5: Phylogenetic findings from the calibrated simulations with bootstrapped empirical data. A) 303 
Frequency of the number of founding variants for transmission pairs by infection stage of source partner at 304 
transmission and risk group. The number of transmitted founding variants is calculated as the modal 305 
simulated value. B)  Probability of one founder variant in the recipient for each pair stratified by infection 306 
stage of the source partner at transmission.  307 
Effect of the number of sequences for each transmission pair 308 
Here we provide sensitivity analysis to the estimation of the probability that a single founder 309 
variant was transmitted to the respective recipient by the number of sequences available from the 310 
source and recipient, which ranges from 5 to 149 across all partners. First, the number of 311 
sequences available from the transmitter and the recipient is correlated (Pearson's product-312 
moment correlation=0.53, P<0.01). However, we do not find any evidence of correlation 313 
between the total number of sequences for a pair and the estimated number of founder variants in 314 
the recipient (P>0.2). While an MM topology is more frequently observed when the total number 315 
of sequences was small (P<0.01), removing the pairs with a likely MM topology do not change 316 
our main result: the probability that a single founder variant was transmitted to the respective 317 
recipient is lower for the acute pairs (0.402) than for the chronic ones (0.749). 318 
Effect of the sequencing method 319 
We evaluated if our results were affected by the type of sequence data used in the analysis. All of 320 
the transmission pair data were generated using Sanger capillary sequencing except for those in 321 
one study ((46) in Data S1) which used Illumina sequencing on end-point diluted primary 322 
isolates. Our results are robust to the exclusion of the eight transmission pairs extracted from this 323 
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study: that is, the probability that a single founder variant is transmitted to the respective 324 
recipient is lower for the acute stage (0.402) than for the chronic stage (0.756). 325 
Effect of the gene region and length 326 
Looking at chronic stage transmissions only, if we compare the number of founder variants 327 
inferred from envelope gene sequences to  those inferred from non-envelope sequences, we don't 328 
find significant differences (P>0.4) in the probability that a single founder variant is transmitted 329 
to the respective recipient: 0.739 for envelope sequences  and 0.856 for non-envelope ones. 330 
Conversely, if we include data from both chronic and acute transmissions, and restrict our 331 
analysis to those pairs with sequences from the envelope region, our results remain unchanged. 332 
That is, the probability that a single founder variant is transmitted to the respective recipient is 333 
lower during the acute stage (0.432) than during the chronic stage (0.739). Finally, if we 334 
condition our analysis on those pairs for whom full or near full genomes are available (17 pairs), 335 
our results remain consistent with the main analysis: the probability that a single founder variant 336 
was transmitted is lower for acute stage transmissions (0.138, n=1) than for chronic stage 337 
transmissions (0.903, n=16). We found that length of the sequenced region is not correlated with 338 
the probability that a single founder variant is transmitted to the recipient (Pearson's product-339 
moment correlation=0.14, P>0.14). Moreover, there are no significant differences (P>0.81) in 340 
the length of the sequenced region when stratifying our data by infection stage of the source 341 
partner at transmission.  Together these observations indicate that our results are not influenced 342 
by the length of sequenced regions. 343 
 344 
 345 
 21 
Data S1 (Separate file): SITable_EpiGeneticData.csv. Collated epidemiological and clinical 346 
data and genetic metadata for the 112 transmission pairs used in the analysis. 347 
Data S2 (Separate file): SITable_AnalysisData.csv. Analysis information for the 112 348 
transmission pairs used in the analysis. 349 
Data S3 (Separate file): SITable_ColumnNamesKey.csv. Additional information on column 350 
headers in Data S1,S2 tables 351 
Data S4 (Separate file): Alignments.zip. Individual files of sequence alignments used in the 352 
analysis for the 112 transmission pairs. 353 
 354 
